Potential to improve the therapeutic situation of HCC patients – The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC

MA Ardelt; Petra Huber-Cantonati; J Pachmayr

Potential to improve the therapeutic situation of HCC patients – The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC

MA Ardelt, Petra Huber-Cantonati, J Pachmayr

Insitute of Pharmacy

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - 2019
Event	ÖPhG Annual Meeting - Graz, Austria Duration: 25 Apr 2019 → 27 Apr 2019

Conference with scientific content

Conference with scientific content	ÖPhG Annual Meeting
Country/Territory	Austria
City	Graz
Period	25/04/19 → 27/04/19

1 Abstract

Potential to improve the therapeutic situation of HCC patients – The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC
Ardelt, M., Huber-Cantonati, P. & Pachmayr, J., 2019.
Research output: Contribution to conference › Abstract

Cite this

@conference{e5faf926b25f4b31a49dd7f37f679a3d,

title = "Potential to improve the therapeutic situation of HCC patients – The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC",

author = "MA Ardelt and Petra Huber-Cantonati and J Pachmayr",

year = "2019",

language = "English",

note = "{\"O}PhG Annual Meeting ; Conference date: 25-04-2019 Through 27-04-2019",

}